DCOY · Decoy Therapeutics Inc.
$1.07
-0.07 (-5.73%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$743,635
Shares
655,185
Volume · Oct 21
46.3K
Avg daily vol (3M)
2.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.14
Open$1.17
Day$1.11–1.17
52W close$1.14–48.60
Avg vol 30d4.6M
Short int150K · 22.9% float · 1.0d
Short vol13%
Last earningsAug 15, 2022
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$14.45M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 16,170.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.29M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4,410.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
22.9%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−81%
below
Price vs 50-day avg
−56%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−63%
trailing
6-month return
−80%
trailing
YTD return
−85%
this year
Relative strength
−88%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.95% of float · ▲ +1321.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — mid 6-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−86%
Y/Y
Free cash flow
$-4.8M
Quant / Vol
risk profile
Volatility
160%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
26.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−81%
Bearish
Price vs 50-day avg
−56%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.95% of float · ▲ +1321.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — mid 6-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $49
vs 200-day avg -81%
vs 50-day avg -56%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DCOY
this stock
Decoy Therapeutics Inc.
|
$743,635 | — | -100.0% | — | 22.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +13.5% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DCOY | -8.5% | -63.4% | -79.5% | -42.4% | -85.4% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -7.3% | -62.8% | -87.6% | -43.2% | -98.2% |